Acute Coronary Syndrome
Acute Coronary Syndrome (ACS) is a condition characterized by a sudden reduction or blockage of blood flow in the coronary arteries, leading to heart muscle damage or dysfunction; it typically presents with centrally located chest pain, often radiating to the left shoulder or jaw and accompanied by nausea and sweating, though symptoms can vary, especially in women, older adults, and individuals with diabetes. Common manifestations of ACS include heart attacks (myocardial infarction) and chest pain (angina).
Health Outcomes
- Changed QT Interval Length
- Changed Secretory Phospholipase A2 Level
- Developed Polymorphic Ventricular Tachycardia
- Improved CVD-Related Symptom
- Improved Cardiac Muscle Contractile Performance
- Improved Cardiovascular Function
- Improved Combined Cardiopulmonary Outcomes
- Improved ECG Finding
- Improved Electrocardiogram
- Improved Event-Free Survival
- Improved Fractional Shortening
- Improved Hemodynamic Stability
- Improved Hospital Discharge
- Improved Left Ventricular Global Longitudinal Strain
- Improved Myocardial Strain Rate
- Improved Oxygen Pulse
- Improved Perceived Recovery
- Improved Post-Myocardial Infarction Outcome
- Improved Prognosis
- Improved Prognosis After Bacteremia Recovery
- Improved Survival at 24 Months
- Improved Tissue Oxygen Saturation Index
- Improved Treatment Effective Rate
- Improved Troponin T Level
- Increased Days Alive and Out of Hospital
- Increased Endothelial Progenitor Cell Count
- Increased Factor VII Level
- Increased Mortality
- Increased Treatment Success Rate
- Inhibited Platelet Aggregation
- Mitigated Cardiac Injury from Myocardial Infarction
- Modified LDL Phosphatidylcholine Composition
- No Change in Major Cardiovascular Event
- No Difference in Adverse Events
- No Long-Term Impact on Gut Microbiota
- Normal Safety Parameters
- Prolonged QT Interval
- Reduced APACHE II Score
- Reduced Aortic Pressure
- Reduced Apolipoprotein A-I Level
- Reduced Apolipoprotein A1 Level
- Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio
- Reduced Atherosclerotic Plaque Formation
- Reduced Bed Rest Occurrence
- Reduced Biofilm Formation on Stents
- Reduced Cardiac Arrest Risk
- Reduced Cardiac Arrhythmia
- Reduced Cardiac Biochemical Marker
- Reduced Cardiac Damage
- Reduced Cardiac Event
- Reduced Cardiac Function
- Reduced Cardiac Issues
- Reduced Cardiovascular Death
- Reduced Cardiovascular Event
- Reduced Chest Pain
- Reduced Contrast-Induced Acute Kidney Injury
- Reduced Decline in Left Ventricular Ejection Fraction
- Reduced Duration of Dobutamine Use
- Reduced HMG-CoA Reductase Inhibition
- Reduced Hospital Mortality Rate
- Reduced Hospital Readmission Risk
- Reduced Hospital Stay
- Reduced Hospital Stay Duration
- Reduced Hospitalization Day
- Reduced Hospitalization Duration
- Reduced Hospitalization Rate
- Reduced ICU Admission
- Reduced In-hospital Mortality
- Reduced Inotropic Support Requirement
- Reduced Intensive Care Unit Length of Stay
- Reduced Intensive Care Unit Mortality
- Reduced Intensive Care Unit Outcome
- Reduced LDL Aggregation
- Reduced Left Ventricular Dilatation
- Reduced Left Ventricular Ejection Fraction Decline
- Reduced Length of Hospitalization
- Reduced Length of Stay
- Reduced Life Threatening Complication
- Reduced Medical Complications
- Reduced Mortality
- Reduced Mortality Rate Before Discharge
- Reduced Mortality Rate under Stress
- Reduced Myeloperoxidase Levels
- Reduced Myocardial Infarct Size
- Reduced Myocardial Injury
- Reduced Myocardial Injury Cytokines
- Reduced One-Year Mortality
- Reduced Organ Dysfunction
- Reduced Organ Failure Severity
- Reduced Platelet Function Marker Level
- Reduced Platelet Hyperactivation
- Reduced Pulse Rate
- Reduced Serum Amyloid A Levels
- Reduced Shock Duration
- Reduced Short-term Mortality
- Reduced Short-term Recurrence
- Reduced Statin Discontinuation Rate
- Reduced Survival Rate
- Reduced TXB2 Level
- Reduced Thrombosis
- Reduced Thromboxane A2 Level
- Reduced Time to Crisis Resolution
- Reduced Unplanned Medical Re-presentations
- Reduced Unplanned Re-presentation
- Reduced Unstable Angina